Frontlight ResearchEarly access
WithdrawnNo phase
Long-term Registry of Patients Treated With Loncastuximab Tesirine
Key facts
- Who runs it
- ADC Therapeutics S.A.
- Where
- Fountain Valley, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- 30 Jun 2022
- Ended
- Jan 2025
- Type of study
- Observational
- Record updated
- 22 June 2022
- Why it stopped
- Sponsor administrative decision
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (4)Hide the full registry criteria
Who can take part
- Must be ≥ 18 years of age at the time of consent
- Initiated or initiating commercially available loncastuximab tesirine treatment
- Written informed consent must be obtained prior to any registry activities
Who cannot take part
- Prior loncastuximab tesirine exposure in clinical trials
Where in United States
- Compassionate Cancer Care Medical GroupFountain Valley, United States
About the trial
What the trial wants to find out
Retrospective and prospective multi-center observational study of patients with B-cell lymphomas treated with loncastuximab tesirine treatment in real-world practice.
The group in the trial
- Patients Treated with Loncastuximab Tesirine
Patients with B-cell lymphomas and other diagnoses who have been treated with loncastuximab tesirine will have their medical chart data entered into the registry.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Long-term Longitudinal Cohort Registry of Patients Treated With Loncastuximab Tesirine
- Record updated
- 22 June 2022